13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q1 2019. See the latest, Q2 2026 →
Reported value
$1.94B
+129% on the quarter before
Positions
17
2 new · 2 sold out
Top 10
97.7%
of the value
Est. gain
+$196.8M
on stocks held all quarter
Est. return
+27.6%
on those stocks since Q4 2018
Positions as of Mar 31, 2019, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2018. Striped tiles are options.
Largest buys
Since Q4 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Lyft Inc~$1.00BNew · 0.0% → 51.9%+12,828,964 shares
- Alector Inc~$22.0MNew · 0.0% → 1.1%+1,174,540 shares
Largest sells
Since Q4 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
Holdings
As of Mar 31, 2019. Changes are in shares against Dec 31, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyft IncCL A COM · shares New | 51.9% | $1.00B | — | ||||||||
| Jd Com IncSPON ADR CL A · shares 0% · price +44.1% | 21.1% | $408.6M | +$125.0M | ||||||||
| Arris Intl IncSHS · shares 0% · price +3.4% | 12.4% | $240.3M | +$7.9M | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price +16.0% | 3.3% | $63.1M | +$8.7M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price +189.0% | 2.8% | $55.0M | +$36.0M | ||||||||
| SnapCL A · shares 0% · price +100.0% | 1.5% | $28.9M | +$14.4M | ||||||||
| Forty Seven IncCOM · shares 0% · price +2.8% | 1.3% | $25.0M | +$680,000 | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares 0% · price −4.2% | 1.2% | $22.5M | −$978,000 | ||||||||
| Alector IncCOM · shares New | 1.1% | $22.0M | — | ||||||||
| DocuSignCOM · shares −65% · price +29.3% | 1.1% | $21.3M | +$4.8M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price +108.3% | 0.74% | $14.3M | +$7.4M | ||||||||
| Gritstone Oncology IncCOM · shares 0% · price −13.9% | 0.64% | $12.4M | −$2.0M | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price −38.5% | 0.44% | $8.5M | −$5.3M | ||||||||
| Cloudera IncCOM · shares 0% · price −1.1% | 0.24% | $4.7M | −$51,000 | ||||||||
| Dexcom IncCOM · shares 0% · price +0.7% | 0.17% | $3.3M | +$23,000 | ||||||||
| BlockCL A · shares 0% · price +33.7% | 0.05% | $925,000 | +$233,000 | ||||||||
| Dropbox IncCL A · shares 0% · price +6.8% | 0.01% | $284,000 | +$18,000 | ||||||||
| Total · 17 positions | 100% | $1.94B | +$196.8M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2018 to Q1 2019: 15 stocks held throughout, up $196.8M (+27.6%).
- Jd Com Inc+$125.0M+44%
- Magenta Therapeutics Inc+$36.0M+189%
- Snap+$14.4M+100%
- Arcus Biosciences Inc+$8.7M+16%
- Arris Intl Inc+$7.9M+3%
- Cloudera Inc−$51,000−1%
- Autolus Therapeutics Plc−$978,000−4%
- Gritstone Oncology Inc−$2.0M−14%
- Evelo Biosciences Inc−$5.3M−39%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |